Ovid Therapeutics Inc. has announced an agreement with Immedica Pharma AB for the sale of its future royalties related to sales of ganaxolone outside China. The transaction provides Ovid with a non-dilutive capital infusion of $7 million, which will support its ongoing operations. Immedica will acquire 100% of the royalty rights held by Ovid and assume financial responsibility for certain intellectual property costs related to ganaxolone. This agreement strengthens Immedica's focus on ganaxolone by acquiring control of additional intellectual property rights.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9484277-en) on June 25, 2025, and is solely responsible for the information contained therein.